source
- Novartis encounters setbacks while AI firm Anthropic searches for a dealmakerThe latest Endpoints Weekly edition highlights a difficult period for Novartis, noting that the company is facing a series of setbacks. Details of the challenges are not provided, but the report s…
- Revolution Medicines secures FDA approval for Rasonque, a RAS inhibitor targeting advanced pancreatic cancerRevolution Medicines announced FDA approval of its RAS inhibitor Rasonque for patients with advanced pancreatic cancer, marking a milestone for the company. The approval is seen as a breakthrough…